Personalized Embryo transfer(ET) after combination of available modalities CD138,Preimplantation Genetic Diseases (PGD),Endometrial Receptivity Array (ERA)to improve in-vitro fertilization(IVF) success.

Personalized embryo transfer (ET) is a modern approach in in-vitro fertilization (IVF) that seeks to improve the chances of successful pregnancy by tailoring the treatment to the patient’s unique genetic and uterine profile. Preimplantation genetic testing (PGT) is a diagnostic procedure that examines embryos in their early development, allowing for the selection and transfer of healthy embryos into the maternal uterus, which reduces the risk of genetic disorders and enhances the chances of a successful pregnancy. Endometrial Receptivity Array (ERA) is a diagnostic test that evaluates the molecular profile of the endometrium (uterine lining) to determine the optimal window for embryo implantation, helping to identify the most favorable timing for embryo transfer and improve the chances of a successful pregnancy in IVF treatments .

CD138, or syndecan-1, is a cell surface protein involved in cell adhesion, migration, and signaling, and is used in reproductive medicine as a marker for assessing endometrial receptivity, crucial for successful embryo implantation during IVF. Its expression in the endometrium helps determine if the uterine lining is properly prepared for embryo attachment, impacting embryo transfer success .This study aims to explore the benefits and feasibility of combining these technologies, CD138, and PGD, and to improve embryo selection, optimize endometrial receptivity, and ultimately enhance pregnancy success rates.